therapeutics targeting cell adhesion
Zonula is a privately held biotechnology company located in Montreal, Quebec, Canada. The company discovers and develops therapies for the treatment of fibrotic diseases.
Fibrosis is the process leading to the accumulation of collagen-based scars within tissues. Targeting cell adhesion represents a new approach to preventing fibrosis. Zonula is developing inhibitors of cell adhesion that turn off collagen production by cells called fibroblasts (shown in the picture).
Fibroblast adhesion is governed by N-cadherin, which can be thought of as a biological glue. Zonula's N-cadherin inhibitors disrupt fibroblast adhesion and collagen production by these cells.
Zonula's N-cadherin inhibitors:
Copyright © 2023 Zonula Inc. - All Rights Reserved.
Powered by GoDaddy Website Builder